BECTON DICKINSON & CO News
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
see moreBECTON DICKINSON & CO Market News
15d
BDX Gains Momentum with Successful AGILITY Trial Results and White House-Backed $19B U.S. Investment Plan
- Becton Dickinson shares reflect renewed investor confidence following positive AGILITY trial results and a confirmed $19 billion U.S. investment tied to tariff relief.
29d
BDX Faces Class I Convenience Kit Correction from FDA Amid No Reported Injuries
Becton Dickinson issues a correction for convenience kits containing recalled sodium chloride ampules; FDA classifies it as Class I, though no injuries reported.
22 Sep at 00:38
BDX Deploys Advanced Pharmacy Robotics with U.S. Rollout of Vmax 160 at Fairview
Becton Dickinson (BDX) has deployed its BD Vmax 160 intelligent robotics system at Fairview, marking first U.S. use. This pharmacy automation advance boosts MedTech presence and may appeal to investors.
08 Sep at 00:38
BDX Clinical Trial Milestone Boosts Advanced Tissue Regeneration Strategy in Late August
Becton, Dickinson (BDX) achieved a key enrollment milestone in its STANCE clinical trial for the GalaFLEX LITE™ scaffold, advancing its tissue‑regeneration pipeline.
25 Aug at 00:38
BDX Appoints New Chief Quality Officer While Advancing Tissue Regeneration Strategy
Becton Dickinson (BDX) named Gary Sorsher as Chief Quality Officer and is accelerating its advanced tissue regeneration strategy via the PREVENT trial.